Introduction Doctor Sal Raichbach – Addiction Treatment – Ambrosia Treatment Center
Introduction Doctor Sal Raichbach – Addiction Treatment – Ambrosia Treatment Center – Visit Ambrosia Treatment Center website for further information. ambrosiatreatmentcenter.com or call 866-577-6868 I’d like to introduce myself. My name is Doctor Sal Raichbach my role here at Ambrosia Treatment Center of the Palm Beaches, is Clinical Director. I started in this field back in 1992 and have worked my way up from earning a License Clinical Social Worker Degree to getting a Doctorate in Psychology. I’ve practiced both in New York and Florida and my main goal in become a psychologist is to be able to integrate mental health as well as addiction services under one scope. Where a person can get mind and body in both mental heath and addiction under one type of treatment modality. Ambrosia Treatment Drug Rehab Center provides drug addiction treatment services in Florida, alcohol detox, drug detox and intensive outpatient drug rehab. http ambrosiatreatmentcenter.com
Study: Aspirin may help treat some colon cancers
Filed under: drug rehab treatment ny
NEW YORK — Aspirin, one of the world's oldest and cheapest drugs, has shown remarkable promise in treating colon cancer in people with mutations in a gene that's thought to play a role in the disease. Among patients with the mutations, those who …
Read more on Lexington Herald Leader
Pfizer: Cancer drug narrowly misses study goal
Filed under: drug rehab treatment ny
NEW YORK (AP) — Pfizer Inc.'s advanced kidney cancer treatment Inlyta missed its main late-stage study goal when compared to another drug in patients who had not been treated for the disease. The New York drugmaker said Wednesday that patients …
Read more on Businessweek
EU okays Bristol-Astra diabetes drug after US rejection
Filed under: drug rehab treatment ny
NEW YORK (Reuters) – European regulators have approved the first in a new class of diabetes medicines that work independently of insulin to control blood sugar, the drug's developers Bristol-Myers Squibb Co and AstraZeneca Plc said on Wednesday. The …
Read more on Reuters